ETHERNIA
Home / Longevity drugs
Longevity drugs

GLP-1 therapies: a clinical benefit is not the same as age reversal.

A large randomized outcome trial provides a useful benchmark for longevity claims.

Established Claim assessed: Reducing major cardiovascular events with semaglutide in SELECT-like patients
Reviewed 2026-09-16 · 2 min read · Ethernia editorial
The current verdict

Semaglutide reduced major cardiovascular events in people with existing cardiovascular disease and overweight or obesity, without diabetes. That is an important, population-specific result.

Human evidenceClinical events reduced

SELECT provides randomized outcome evidence.

Animal evidenceNot the basis of this claim

Human data take priority here.

MechanismMultiple effects

Weight and metabolic pathways may contribute.

Safety evidenceKnown adverse effects

Gastrointestinal and other label risks apply.

Longevity evidenceMaximum lifespan untested

Clinical risk reduction is not systemic rejuvenation.

Impact domainEstablished healthspan impact

Human evidence supports a meaningful clinical or functional outcome in a defined population. It does not imply a change in maximum lifespan.

How to read impact →

What is being assessed?

GLP-1 receptor agonists are a drug class; individual agents, indications and exposures differ. This dossier’s Established label applies specifically to semaglutide and major cardiovascular events in the SELECT population. It is not a class-wide endorsement or a claim about healthy adults with low baseline risk. [1]

A result with clinical weight

SELECT randomized 17,604 adults with established cardiovascular disease and overweight or obesity, without diabetes. Primary events occurred in 6.5% with semaglutide and 8.0% with placebo over a mean follow-up of about 40 months. The hazard ratio was 0.80. The observed absolute difference was 1.5 percentage points, not 20 percentage points. [1]

Why this belongs in longevity research

An intervention that reduces serious events has more direct clinical support than one that only changes a blood marker. Yet this does not settle whether it changes an underlying rate of ageing. Treating a major source of disease burden can improve outcomes without repairing every ageing mechanism. Its impact also depends on the person’s starting risk.

Mechanism and the animal boundary

The drug acts on GLP-1 receptors and affects appetite and glucose regulation. How much of a cardiovascular benefit comes through weight change versus other pathways is a separate causal question. Animal mechanism studies cannot replace that analysis, and no mouse percentage is needed to justify a benefit already demonstrated in a randomized human trial. [2]

Studied exposure and trade-offs

SELECT targeted 2.4 mg subcutaneous semaglutide weekly, with escalation. Treatment discontinuation from adverse events was more frequent with semaglutide. This is the studied regimen, not advice to self-treat. The comparison should include benefit, treatment burden and tolerability rather than focusing only on weight lost. [1]

Specific safety questions

The prescribing information describes severe gastrointestinal effects, gallbladder disease, pancreatitis and dehydration-related kidney injury. It includes a rodent thyroid C-cell tumour warning, with human relevance uncertain, and contraindications involving medullary thyroid carcinoma or MEN2. These risks need to be distinguished from unsupported claims that every adverse event is a class-wide certainty. [2]

Trial watch and what would change the interpretation

The SELECT registry, NCT03574597, provides the protocol and results context. Other indications and populations require their own trials. To support a broad ageing-modification claim, Ethernia would look for replicated effects across prespecified age-related clinical outcomes, including function, with long follow-up. Until then, established cardiovascular benefit and unproven systemic rejuvenation can both be true. [3]

Sources & study records

  1. Lincoff et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without DiabetesNew England Journal of Medicine · Randomized controlled trial; industry funded
  2. Novo Nordisk (2026). Wegovy prescribing informationManufacturer prescribing information · Drug safety reference; June 2026 revision
  3. SELECT investigators (2026). Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or ObesityClinicalTrials.gov · Registry for a published trial

Evidence reviewed 2026-09-16. Registry status can change; follow the linked record for current details.

Follow the question

All evidence →